Luye Pharma Group Ltd.

2186

BMG570071099

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:09 2024-05-16 am EDT			5-day change	1st Jan Change
2.97 ^HKD	-0.34%		-2.62%	-20.38%

Mar. 27	Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	CI

Luye Pharma Group Ltd. Announces Resignation of Kong Teck Chien as Non-Executive Director

February 28, 2012 at 06:39 pm EST

Luye Pharma Group Ltd. announced that Mr. Kong Teck Chien resigned as a Non-Executive Director of the company, effective February 28, 2012.

Latest news about Luye Pharma Group Ltd.

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	Mar. 06	CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	Mar. 04	MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	Mar. 04	CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	Feb. 02	MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	Feb. 01	CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	Dec. 13	MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	Dec. 13	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	Dec. 12	MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	Dec. 12	CI
Luye Pharma Group Ltd. Announces Board Changes	Dec. 06	CI
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	Dec. 04	MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	Dec. 04	MT
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	Nov. 01	MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	23-10-31	CI
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	23-10-09	MT
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	23-10-09	CI
China Approves Luye Pharma's Breast Cancer Injectable	23-09-08	MT
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio	23-09-07	CI
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin	23-08-21	CI
Luye Pharma's Rykindo Enters US Market; Shares Down 3%	23-08-18	MT
Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States	23-08-17	CI
Chinese Regulator Accepts Luye Pharma's New Drug Application for Parkinson's Disease Injectable	23-08-01	MT
Luye Pharma Group Ltd. Announces Acceptance of the NDA and Priority Review for Rotigotine Extended-Release Microspheres for Injection by National Medical Products Administration	23-08-01	CI

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Companyâs main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimerâs disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Luye Pharma Group Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.759 CNY

Average target price

2.822 CNY

Spread / Average Target

+2.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUYE PHARMA GROUP LTD.	-20.38%	1.44B
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+30.96%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.42%	239B
NOVARTIS AG	+9.41%	211B
ROCHE HOLDING AG	-4.29%	203B
AMGEN INC.	+10.77%	171B

Other Pharmaceuticals